Janssen

CARVYKTI

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / CARVYKTI – Q2056

Manufacturer:

Janssen

Name:

CARVYKTI

HCPCS Code Descriptor:

Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

HCPCS:

Q2056

NDC(s):

57894-0111-02, 57894-0111-01

Primary Type:

Oncology

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

CARVYKTI is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The Q Code: Q2056 is aligned to the drug CARVYKTI.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

10/1/22

HCPCS Effective Date:

10/1/22

HCPCS Short Description:

Ciltacabtagene car-pos t

Billing and Coding Guide:

Not Found

Patient Assistance:

Not Found